Intracellular islatravir-triphosphate half-life supports extended dosing intervals
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.00458-24 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Xiaowei Zang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Merck & Co., Inc., Rahway, New Jersey, USA. Hauptthemen laut MEDLINE: Anti-HIV Agents, Leukocytes, Mononuclear. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Antiretroviral therapy has substantially reduced morbidity, mortality, and disease transmission in people living with HIV. Islatravir is a nucleoside reverse transcriptase translocation inhibitor that inhibits HIV-1 replication by multiple mechanisms of action, and it is in development for the treatment of HIV-1 infection. In preclinical and clinical studies, islatravir had a long half-life (t ½ ) of 3.0 and 8.7 days (72 and 209 hours, respectively); therefore, islatravir is being investigated as a long-acting oral antiretroviral agent. A study was conducted to definitively elucidate the terminal t ½ of islatravir and its active form islatravir-triphosphate (islatravir-TP). A single-site, open-label, non-randomized, single-dose phase 1 study was performed to evaluate the pharmacokinetics and safety of islatravir in plasma and the pharmacokinetics of islatravir-TP in peripheral blood mononuclear cells after administration of a single oral dose of islatravir 30 mg. Eligible participants were healthy adult males without HIV infection between the ages of 18 and 65 years. Fourteen participants were enrolled. The median time to maximum plasma islatravir concentration was 1 hour. Plasma islatravir concentrations decreased in a biphasic manner, with a t ½ of 73 hours. The t ½ (percentage geometric coefficient of variation) of islatravir-TP in peripheral blood mononuclear cells through 6 weeks (~1008 hours) after dosing was 8.1 days or 195 hours (25.6%). Islatravir was generally well tolerated with no drug-related adverse events observed. Islatravir-TP has a long intracellular t ½ , supporting further clinical investigation of islatravir administered at an extended dosing interval.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Merck & Co., Inc., Rahway, New Jersey, USA.
- Department of Pharmacology, Physiology & Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Randolph P Matthews
Zitieren
APA
Zang, X., Ankrom, W., Kraft, W. K., Vargo, R., Stoch, S. A., Iwamoto, M., & Matthews, R. P. (2024). Intracellular islatravir-triphosphate half-life supports extended dosing intervals. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00458-24
Vancouver
Zang X, Ankrom W, Kraft WK, Vargo R, Stoch SA, Iwamoto M, et al. Intracellular islatravir-triphosphate half-life supports extended dosing intervals. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00458-24
BibTeX
@article{Zang2024,
author = {Zang, Xiaowei and Ankrom, Wendy and Kraft, Walter K and Vargo, Ryan and Stoch, S Aubrey and Iwamoto, Marian and Matthews, Randolph P},
title = {Intracellular islatravir-triphosphate half-life supports extended dosing intervals},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.00458-24}
}
EUVIMED